RESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

rESEARCH AND INNOVATION

Concept Foundation’s Research and Innovation team identifies, develops and evaluates new and neglected high potential sexual and reproductive health (SRH) medicines and technologies.

We scan and review the field to identify SRH products that are likely to be safe and effective and in parallel reduce inequities in our efforts to achieve Universal Health Coverage.

Photo Credit: Joni Kabana

Basic and clinical research

  • We evaluate the benefits and harms of existing and new interventions
  • We develop new interventions for which there is a market need
    • New treatments
    • Diagnostics
    • Point-of-care tests
  • We use modern technologies to improve drug stability

Innovation

  • We perform landscape analysis of pipeline and marketed products
    • Contraception
    • Safe Medical Abortion
    • Maternal Health
  • We identify gaps in treatment options and other needs in maternal and reproductive health
  • We search for, and evaluate, new promising innovations

OUR RESEARCH APPROACH

Concept Foundation is mandated to work on quality-assured reproductive health medicines and technologies.

 

Between 2010 and 2020, CF conducted quality assessments of a large range of essential reproductive health medicines through our work within the Quality of Reproductive Health Medicines Programme (QuRHM) and the UN Commission for Life Saving Commodities. We continue to work on field collection of medicines and conduct testing with our partner laboratories.

Our second approach is to identify new and existing but inadequately evaluated and partly forgotten medicines. We believe that there should be more research and innovation to develop solutions for pregnancy-specific conditions like pre-eclampsia/eclampsia, preterm labour and birth, and obstetric haemorrhage. Similarly, we are working to improve contraceptive and pregnancy termination options through innovative approaches.

We are working on exploring and potentially expanding self-care for sexual and reproductive health medicines and technologies by conducting landscaping and systematic reviews. Our research approach is collaborative. We work closely with HRP/WHO, Birmingham University, UK, Monash University Institute of Pharmaceutical Sciences and the Burnet Institute, Australia and other partner organizations globally.

OUR CURRENT FOCUS

PPH FIRST RESPONSE BUNDLE

An implementation research project to evaluate the impact of the first response PPH treatment bundle on substantive health outcomes.

The PPH first response bundle includes the administration of oxytocin (OXY), tranexamic acid (TXA), uterine massage and fluids.

The clinical study will take place in numerous health facilities in Kenya, Nigeria, Tanzania, South Africa and Sri Lanka.

CF will identify, select and evaluate the quality of the OXY and TXA products used in the facilities.

CF is conducting this project in a collaboration with the University of Birmingham (UK) and Monash University (Australia).

EARLY MENSTRUAL INDUCTION

Emergency contraception offers an effective solution in cases of unprotected intercourse. Emergency contraceptive pills and intrauterine device (IUD) provide a reliable option when taken within 3-5 days. However, after missing this 3-5 day window, women need to wait for expected menses and must take a pregnancy test to confirm pregnancy before being able to take the appropriate course of action from the options available.  

We aim to identify a new option that induces menses, and which can be used >5 days following unprotected intercourse.

CF is leading this project in collaboration with WHO HRP, CEMAG Care (France) and Chulalongkorn University  (Thailand).

LANDSCAPE ANALYSIS

We are conducting an extensive landscape analysis of pipeline and marketed new innovations (medication, devices, diagnostics) in the field of contraception, abortion, maternal health (i.e. pre-eclampsia, postpartum hemorrhage), sexually transmitted infections and cervical cancer. 

Our findings will lead to publications concerning state-of-the-art innovations in sexual and reproductive health, and to new collaborations in which we can help innovators to bring their products to low- and middle-income settings.